findmyKOL

Robert Matalon, MD

Basic profile

Nephrology

ORCIDNone on fileNPI
RegionNew York, NY · NortheastSpecialtyNephrologyFocusNephrology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2008Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Robert Matalon is a Nephrology physician. OpenAlex indexes 25 publications with 352 citations (h-index 12).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
25publications

Distinct works indexed by OpenAlex.

352citations

Total citations across indexed works.

12h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

323 E 34th St Fl 2
New York, NY 100164974

Telephone

212-263-7239

Provider last certified this registry record 16 Sept 2021.

View the NPPES registry record

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    48.8%
    Statin16.1%
    Atorvastatin Calcium79%Simvastatin21%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)9.4%
    Valsartan85%Losartan Potassium15%
    Part D<11 patients

    + 8 more classes in this area

  • Metabolism & gastrointestinal

    24.7%
    SGLT2 inhibitor6.3%
    Jardiance100%
    Part D12 patients
    Biguanide (metformin)4%
    Metformin Hcl100%
    Part D<11 patients

    + 7 more classes in this area

  • Blood & clotting

    8%
    Factor Xa inhibitor4.6%
    Eliquis100%
    Part D<11 patients
    Vitamin K antagonist2%
    Warfarin Sodium100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)21.7% facility · 78.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

20 more publications behind the reveal.Reveal →

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”